Tecfidera Insurance Denial Appeal Guide

Tecfidera (dimethyl fumarate) is an oral treatment for relapsing multiple sclerosis. With generic availability, insurance denials have shifted from cost to formulary preference issues.

Why Tecfidera Gets Denied

Since generic dimethyl fumarate became available, brand Tecfidera is almost never covered. However, even the generic version may face prior authorization requirements or formulary preference for newer oral MS therapies.

Common Denial Reasons

  • Brand not covered (generic required)
  • Plan prefers a different oral DMT (Gilenya, Vumerity, Aubagio)
  • Prior authorization not submitted for generic
  • Step therapy through interferon or glatiramer acetate
  • Quantity/dose limits

How to Appeal

  1. Ensure generic is being prescribed — brand appeals will almost certainly fail
  2. Document why this DMT specifically — tolerability profile, prior medication history
  3. If step therapy required — document intolerance or contraindications to interferons
  4. Neurologist letter explaining DMT selection rationale
  5. Cite pivotal DEFINE and CONFIRM trial data

Generic Transition

If you were stable on brand Tecfidera and switched to generic with problems, document this. However, most appeals now should focus on generic dimethyl fumarate access rather than brand.

Need Help Writing Your Appeal?

Our AI-powered tool analyzes your denial letter and generates a personalized appeal in minutes. Upload your denial and get started for free.

Start Your Free Appeal

Frequently Asked Questions

Is there a generic for Tecfidera?

Yes, generic dimethyl fumarate is available and significantly cheaper. Most insurers now require the generic version. If you have problems switching to generic, document side effects for a brand exception appeal.

What are common side effects that might cause switching?

GI side effects (nausea, diarrhea) and flushing are common with dimethyl fumarate. These often improve over time but can be dose-limiting for some patients.

Related Resources